Metastatic prostate

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel‑Containing Regimen.

Localized or locally advanced RCC

A randomized, double blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy.

• Phase III study
• Selection criteria

Prostaat

Evaluation of docetaxel in the treatment of patients with hormone refractory prostate cancer.

• Study Phase IV
• Selection criteria

Metastatic kidney

An open-label, multicenter, expanded access study of RAD 001 in patients with metastatic carcinaoma of the kidney who are tolerant of or have progressed despite any available vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFr-TKI) therapy.

• Study Phase IIIB
• Selection criteria